Do This Today BEFORE Biden Wins in November

Discover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).

Find out how you can too in this free video.

Amit Sachdev Biography and Net Worth

EVP of Vertex Pharmaceuticals

Mr. Sachdev joined Vertex in 2007 and is the Company’s Executive Vice President and Chief Patient Officer. In this role, Mr. Sachdev leads the company’s efforts to strengthen relationships with the CF community and build new ones globally with patients and advocates across the diseases Vertex is pursuing. He serves on the company’s Executive Committee and has held various leadership posts across the business over the past decade. In addition to Patient Advocacy and Engagement, he also oversees Government Affairs and Public Policy, and established Vertex’s first international commercial operations in 2010.

Prior to joining Vertex, Mr. Sachdev served as Executive Vice President at the Biotechnology Innovation Organization (BIO) and was Deputy Commissioner for Policy at the U.S. Food and Drug Administration (FDA) where he held several other senior executive appointments. Earlier in his career, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives and practiced law at the American Chemistry Council and also at the law firm Ropes & Gray.

Mr. Sachdev received a B.S. from Carnegie Mellon University and a J.D. from Emory University School of Law.

What is Amit Sachdev's net worth?: The estimated net worth of Amit Sachdev is at least $31.27 million as of February 12th, 2024. Mr. Sachdev owns 74,364 shares of Vertex Pharmaceuticals stock worth more than $31,270,062 as of May 10th. This net worth estimate does not reflect any other investments that Mr. Sachdev may own. Learn More about Amit Sachdev's net worth.
How do I contact Amit Sachdev?: The corporate mailing address for Mr. Sachdev and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Amit Sachdev's contact information.
Has Amit Sachdev been buying or selling shares of Vertex Pharmaceuticals?: Amit Sachdev has not been actively trading shares of Vertex Pharmaceuticals during the past quarter. Most recently, Amit Sachdev sold 3,222 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a transaction totalling $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company's stock, valued at $31,250,727.36. Learn More on Amit Sachdev's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 24 times. They sold a total of 97,797 shares worth more than $36,523,319.58. The most recent insider tranaction occured on February, 26th when EVP Ourania Tatsis sold 354 shares worth more than $150,697.80. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 2/26/2024.

Amit Sachdev Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2024	Sell	3,222	$420.24	$1,354,013.28	74,364
11/15/2021	Sell	51	$187.19	$9,546.69
4/27/2021	Sell	3,884	$216.06	$839,177.04	44,017
8/3/2020	Sell	1,941	$278.28	$540,141.48	37,044
5/11/2020	Sell	10,665	$282.61	$3,014,035.65	45,768
5/5/2020	Sell	13,356	$270.01	$3,606,253.56	67,603
2/25/2020	Sell	3,376	$233.53	$788,397.28	36,291
2/18/2020	Sell	3,489	$243.56	$849,780.84	42,936
1/16/2020	Sell	5,000	$235.00	$1,175,000.00	41,190
1/8/2020	Sell	5,000	$230.00	$1,150,000.00	41,190
12/9/2019	Sell	5,000	$225.00	$1,125,000.00	38,416
11/25/2019	Sell	5,000	$220.00	$1,100,000.00	38,416
11/19/2019	Sell	5,000	$215.00	$1,075,000.00	38,416
11/4/2019	Sell	4,097	$200.34	$820,792.98	35,571
10/25/2019	Sell	4,311	$197.89	$853,103.79	37,727
10/22/2019	Sell	3,883	$190.27	$738,818.41	37,299
5/15/2019	Sell	61	$165.41	$10,090.01	33,416
6/29/2018	Sell	4,096	$167.63	$686,612.48	48,603
3/9/2018	Sell	13,750	$175.00	$2,406,250.00	60,412
2/5/2018	Sell	4,520	$163.01	$736,805.20	46,202
1/29/2018	Sell	15,085	$170.00	$2,564,450.00	54,248
1/22/2018	Sell	46,172	$158.65	$7,325,187.80	57,835
1/19/2018	Sell	32,422	$158.08	$5,125,269.76	57,835
10/31/2017	Sell	40,000	$145.05	$5,802,000.00	89,810
7/21/2017	Sell	28,625	$160.93	$4,606,621.25	119,335
3/29/2017	Sell	80,500	$107.63	$8,664,215.00	105,054
5/16/2016	Sell	117	$81.67	$9,555.39	86,096
3/23/2015	Sell	17,083	$132.28	$2,259,739.24
3/18/2015	Sell	12,000	$130.00	$1,560,000.00
1/9/2015	Sell	12,000	$125.00	$1,500,000.00
11/28/2014	Sell	12,000	$120.00	$1,440,000.00
10/28/2014	Sell	12,000	$115.00	$1,380,000.00
9/30/2014	Sell	86,000	$112.68	$9,690,480.00
7/19/2013	Sell	22,250	$88.69	$1,973,352.50

Amit Sachdev Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $422.78

$417.50

$423.32

50 Day Range

MA: $407.82

$392.81

$432.76

2 Week Range

Now: $422.78

$320.01

$448.40

Volume

1,064,425 shs

Average Volume

1,058,237 shs

Market Capitalization

$109.27 billion

P/E Ratio

27.44

Dividend Yield

N/A

Beta

0.39